{"id":1003136,"date":"2026-09-14T07:21:08","date_gmt":"2026-09-14T11:21:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/"},"modified":"2026-09-14T07:21:08","modified_gmt":"2026-09-14T11:21:08","slug":"cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/","title":{"rendered":"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer"},"content":{"rendered":"<h2>\nCompany to host a virtual event today at 8:00 a.m. ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., Sept.  14, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N6kZUeLrXGbVrcXamntS4W_cESdlhiFvPT78zFnjB8iu5D28Q36OzkVOFcJZFs1esncJoTR86VfItcmN7_458IWZYuNwvQ1uMTSHyD_5_VGphC-tKUl9o_lZYdtf5Zlz\" rel=\"nofollow\" target=\"_blank\">Cullinan Therapeutics, Inc.<\/a> (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer\u2019s (IASLC) 2026 World Conference on Lung Cancer (WCLC).<\/p>\n<p>\n        <strong>Virtual Event Details<\/strong>\n      <\/p>\n<p>Cullinan Therapeutics will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET. Participants from Cullinan Therapeutics include Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer.<\/p>\n<p>A live webcast will be available via the events page of Cullinan Therapeutics\u2019 investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uF1UH3vjp2--OOB-Msv9rldjtXm4LNXyMFgi7nr8muX73KpyYDSebwZ_zy5WcgFy0LiDVSW4iBAbb6DF2b51hsGy-NVepys83ZK550VVm0kCN5iSLiY6N2jRo-uIbwxVa7OnDR2QOmeAA48Av4DA4u5VeK5nq2FuH0Qydm8wtV4=\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.cullinantherapeutics.com\/events<\/a>. A replay will be archived on the website following the event.<\/p>\n<p>\n        <strong>About Cullinan Therapeutics<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N6kZUeLrXGbVrcXamntS4W_cESdlhiFvPT78zFnjB8j-N6yITHoLOGrGLNz5q7yrTfN4Jh5e-TZesDdPklITpXq9BwRpmJNTlYNqj4Rr--q0a4E5F65YeTW9hXvQ-nHv\" rel=\"nofollow\" target=\"_blank\">Cullinan Therapeutics, Inc.<\/a>\u00a0(Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uF1UH3vjp2--OOB-Msv9rlp5IaQZK123aW70EDaF7GQCEr8sjFGFgvmodID7qFGCFHcbL_7o2Nt3T0QPLuCKGfGJ8AkY9-M3WKAT9swjvhxXNgoHfc0jm-qNKszgNaB9\" rel=\"nofollow\" target=\"_blank\">https:\/\/cullinantherapeutics.com\/<\/a>, and follow Cullinan on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rnNcaITlEoNL0sMLIPhvwxM1VGIxT2bRtUv02xnoN0yd3buthdOi7PV-gPci5ffmYiFtNeRobxp0axm7vP-GhBqTqNkeWNE8YPQEyQP13M8=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pHmEmnlashrBddLEo9aVRY0vP6SaeS93roNWFR_22MIaUyGwAH23OH8_ELM3wx_WY4Nv537CRo29AfGJzCUBjQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Cullinan Therapeutics<\/strong><br \/>\n        <br \/>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Nick Smith<br \/>+1 401.241.3516<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nfApll_BF6ROAkNiU1QosyuQA-IfYjqevGdbCByGK5WHdB-EC17CGf1cRNg6-gWLfH6u-I_2RfSNRltTC7yPD-uIT35HJ9O9kUyNmki4wPc=\" rel=\"nofollow\" target=\"_blank\">Nsmith@cullinantx.com<\/a><\/u><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Rose Weldon<br \/>+1 215.801.7644<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z__-exTsmRVWGItd_tEAyS7WxX1WWHby86LYDW9yf6Z1PVeeTiS5oqz9I1X0hVCaxioaS5M_2alStjKz0g7KJyLdgWmpGOSxBZ5Huft6wUw=\" rel=\"nofollow\" target=\"_blank\">Rweldon@cullinantx.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2VlOGJjZDEtMDUyOC00MjE4LTkxNWYtNzJhOTJmZTIyYmY3LTEyMTc0MjYtMjAyNi0wOS0xNC1lbg==\/tiny\/Cullinan-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to host a virtual event today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) &#8212; Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer\u2019s (IASLC) 2026 World Conference on Lung Cancer (WCLC). Virtual Event Details Cullinan Therapeutics will host a virtual event for analysts and institutional investors today at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1003136","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host a virtual event today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) &#8212; Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer\u2019s (IASLC) 2026 World Conference on Lung Cancer (WCLC). Virtual Event Details Cullinan Therapeutics will host a virtual event for analysts and institutional investors today at &hellip; Continue reading &quot;Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-14T11:21:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer\",\"datePublished\":\"2026-09-14T11:21:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/\"},\"wordCount\":304,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/\",\"name\":\"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=\",\"datePublished\":\"2026-09-14T11:21:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Market Newsdesk","og_description":"Company to host a virtual event today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) &#8212; Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer\u2019s (IASLC) 2026 World Conference on Lung Cancer (WCLC). Virtual Event Details Cullinan Therapeutics will host a virtual event for analysts and institutional investors today at &hellip; Continue reading \"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-14T11:21:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer","datePublished":"2026-09-14T11:21:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/"},"wordCount":304,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/","name":"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=","datePublished":"2026-09-14T11:21:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTgzNSM3ODMwODE1IzIyMDU4NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalertinib-plus-chemotherapy-phase-3-rezilient3-data-presented-at-the-iaslc-2026-world-conference-on-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1003136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1003136"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1003136\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1003136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1003136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1003136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}